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Abstract
Our daily decisions are governed by the arbitration between goal-directed and habitual strategies. However, the
neurochemical basis of this arbitration is unclear. We assessed the contribution of dopaminergic, serotonergic, and
opioidergic systems to this balance across reward and loss domains. Thirty-nine participants (17 healthy controls, 15
patients with pathological gambling, and 7 with binge eating disorder) underwent positron emission tomography
(PET) imaging with [18F]FDOPA, [11C]MADAM and [11C]carfentanil to assess presynaptic dopamine, and serotonin
transporter and mu-opioid receptor binding potential. Separately, participants completed a modified two-step task,
which quantifies the degree to which decision-making is influenced by goal-directed or habitual strategies. All
participants completed a version with reward outcomes; healthy controls additionally completed a version with loss
outcomes. In the context of rewarding outcomes, we found that greater serotonin transporter binding potential in
prefrontal regions was associated with habitual control, while greater serotonin transporter binding potential in the
putamen was marginally associated with goal-directed control; however, the findings were no longer significant when
controlling for the opposing valence (loss). In blocks with loss outcomes, we found that the opioidergic system,
specifically greater [11C]carfentanil binding potential, was positively associated with goal-directed control and
negatively associated with habit-directed control. Our findings illuminate the complex neurochemical basis of goal-
directed and habitual behavior, implicating differential roles for prefrontal and subcortical serotonin in decision-
making across healthy and pathological populations.
Introduction
Two distinct systems influence our choice behavior:
goal directed and habitual control. Goal-directed (or
model-based) control is characterized by a learned inter-
nal model of the environment that can dynamically
evaluate optimal actions, a flexible but computationally
expensive strategy1–3. By contrast, habitual (or model-
free) control computes the value of each action entirely by
past experience (reward prediction errors), sacrificing
flexibility for greater efficiency. Disruptions in the balance
of these strategies may underlie a range of pathological
behaviours, in particular psychiatric disorders character-
ized by compulsivity3–5.
This balance between goal-directed and habitual stra-
tegies is mediated by various neurochemical processes.
Among these, the dopamine system is most frequently
implicated; a smaller number of studies also point to the
involvement of the serotonin and opioid systems3,6. The
role of dopamine in this balance is a topic of some debate.
Traditionally, dopamine has been associated with model-
free reinforcement learning: in rodents, pharmacologi-
cally enhancing dopamine increases habit formation7,
while dopaminergic nigrostriatal lesions impair habit
formation8. However, more recent human research has
shown that depleting dopamine increases habitual con-
trol9, while administration of the dopamine precursor
levodopa was reported to enhance goal-directed control
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in two studies10,11 and reduce habitual control in a
third12 (in the latter study, participants with high working
memory capacity did show enhancement of goal-directed
control). There is evidence that a key locus of this
influence is the ventral striatum: a study that combined 6-
[18F]fluoro-L-dopa ([18F]FDOPA) positron emission
tomography (PET) with functional magnetic resonance
imaging found goal-directed learning correlated with
ventral striatal presynaptic dopamine synthesis capa-
city13. In line with this work, we expected that heightened
dopamine levels might shift decision-making toward a
goal-directed and away from a habitual strategy. How-
ever, most previous work has focused exclusively on
choice behavior in the reward domain14–16, a crucial
limitation, making the involvement of dopamine in the
loss domain unclear. Thus, probing the neurochemical
substrates of model-based and model-free control across
reward and loss domains may yield a fuller picture of the
neural basis of decision-making.
The opioid and serotonin systems appear to play a role
in arbitrating between goal-directed and habitual control
of behaviour. In rodents, decreasing forebrain serotonin
(5-HT) increases compulsive cocaine seeking and
manipulating the serotonergic system shifts these habitual
behaviours16. Overexpression of rodent dorsolateral
striatal 5-HT6 receptors also decreases habitual control15.
In healthy humans, central serotonin depletion enhances
habitual responding17. However, central serotonin deple-
tion impairs goal-directed control to rewards, but
enhances goal-directed control to losses6, illustrating the
importance of including both reward and loss domains
experimentally. The opioid system also plays an essential
role in goal-directed behaviour. A large body of evidence
implicates the opioid system in goal-directed aspects of
reward processing: opioid peptide-containing neurons,
their terminals, and opioid receptors are present in the
same basal forebrain regions implicated in learning and
performance of goal-directed actions (e.g., the nucleus
accumbens (NAcc) core)18,19.
Compellingly, in rodents, blockade of the opioid system
during learning with naloxone compromises goal-directed
learning, enhancing habitual control of actions14. Nalox-
one administration also decreases goal-directed alcohol
consumption in an animal model of alcoholism, and
blocks reinstatement of alcohol-seeking learned in a goal-
directed schedule20. Opioid processes seem critical for the
acquisition of normal goal-directed control of actions:
potentially, higher endogenous opioid levels would have
the opposite effect to naloxone administration, enhancing
goal-directed control of actions.
Here, we investigate the balance of goal-directed (model-
based) and habitual (model-free) control in the appetitive
and aversive domain (monetary rewards and losses), and
its relationship with NAcc and ventromedial prefrontal
cortex (vmPFC)/medial orbitofrontal cortex (mOFC) pre-
synaptic dopamine function, and serotonin transporter
(SERT) and mu-opioid receptor (MOR)-binding potential
(BP). Previous studies investigating dopamine or serotonin
function in association with model-free/model-based
control have primarily focused on the striatum (e.g.,13,15).
We additionally include a vmPFC/mOFC ROI, due to
previous work suggesting the vmPFC is involved at least in
part in model-based evaluation in this task2. Moreover, in
healthy populations, lower medial OFC and vmPFC
volumes (as well as striatal volumes) are associated with
reduced model-based control4, while reduced medial
prefrontal cortex activation during model-based control is
predictive of relapse in alcohol-dependent patients21,
underlining the clinical relevance of this region’s compu-
tations during the task.
We include three populations of subjects: healthy con-
trols, patients with pathological gambling (PG), and those
with binge-eating disorder (BED); in both BED and
addictive disorders, decision-making is shifted away from
goal-directed toward habitual control (and is thought to
be a transdiagnostic symptom dimension common across
disorders of compulsivity)4. However, the primary pur-
pose of this study was not to assess between-group dif-
ferences, which we explored separately22, but rather to
illuminate the role of these three neurochemical systems
(dopamine, serotonin, and opioid) in goal-directed and
habitual control, across reward and loss domains. Thus,
we included psychiatric populations in our sample in
order to capture a wider range of goal-directed and
habitual behavior (associated with healthier and patholo-
gical states, respecitvely). We hoped this approach would
yield greater insight into the neurochemical substrates of
this behaviour.
We hypothesized that heightened [18F]FDOPA uptake
(signifying greater pre-synaptic dopamine function)
would be associated with heightened goal-directed
learning to rewards; that lower [11C]MADAM BP
(which binds selectively to the SERT) would be associated
with decreased goal-directed control; and that lower [11C]
carfentanil BP (which binds to the MOR) would be
associated with decreased goal-directed control.
Materials and methods
Participants
Sixty-seven prospective participants were screened for
the study. Subjects recruited to BED and PG groups ful-
filled the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV) criteria for BED and PG, respectively,
confirmed in a structured clinical interview. Exclusion
criteria common to both groups, as well as healthy
volunteers, included any substance use disorder during
the last 6 months prior to PET imaging, diagnosed
DSM-IV axis I psychiatric disorder, any clinically relevant
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somatic disorder (e.g., diabetes mellitus), pregnancy or
lactation, and weight over 180 kg (the scanner limit). After
screening, 17 healthy controls, 15 PG patients, and 7 BED
patients were recruited to the study. The study protocol
was approved by the local ethical committee, and all
participants gave written informed consent. We required
36 subjects to detect a large effect size (f2= 0.3) with 80%
power (G*Power: Linear multiple regression). The study
was conducted according to the principles of the
Declaration of Helsinki.
Two-step task
Healthy participants performed the two-step task in two
conditions, monetary reward or loss; all patient groups
performed only the reward version of the task. We have
previously described the task4,23. Briefly, the task con-
sisted of two stages (see Fig. 1a). In stage 1, participants
chose between two stimuli, each of which led to one of
two stimulus pairs with a fixed probability (p= 0.70) and
to the other stimulus pair with opposite probability (p=
0.30). In stage 2, participants chose a single stimulus from
the resulting pair; this choice led to an outcome.
Each of the four stimuli in stage 2 was attached to a
different probability distribution, with probability varying
slowly and independently over time between 0.25 and
0.75. The association between each stage 2 stimulus and
its reward probability was counterbalanced across parti-
cipants. Choices at each stage had to be made within 2 s,
and the result of each choice was presented for 1 s, after a
1.5 s delay. The stimuli chosen in stages 1 and 2 remained
on screen as a reminder in stage 2 and the outcome stage,
respectively. If the stage 2 choice was rewarded, partici-
pants saw a 1 Euro coin for 1 s; otherwise, they saw a grey
circle for 1 s. In the reward condition, subjects either saw
a 1 Euro coin with a green square (win outcome), or a grey
circle (no-win outcome). In the loss condition, subjects
either saw a 1 Euro coin with a red square and red cross
over the coin (loss outcome), or a grey circle (no-loss
outcome).
The task consisted of two blocks of 67 trials each per
condition. The order of the conditions was randomized
(but the two blocks of each condition were always run
sequentially). Prior to the task, participants underwent
extensive computer-based instructions, which included
Fig. 1 Two-step task and regions of interest. a Subjects choose between a stimuli-pair at the first stage which leads with fixed probability (p=
0.70) to one of two states at the second stage. Subjects then choose between one of two stimuli-pairs at the second stage which are associated with
a shifting probability of reward based on a random Gaussian walk. The reward outcome is shown. b Region of interests Top: freesurfer parcellation.
Middle and bottom: Regions of interest. The caudate is shown in blue; the putamen is shown in green; the nucleus accumbens (ventral striatum) is
shown in yellow. The medial orbitofrontal cortex parcellation shown in the Free Surfer parcellation (top) consisted of both the ventromedial
prefrontal cortex and medial orbitofrontal cortex (shown in red at the bottom). For illustration purposes, the Free Surfer reconstruction is shown
overlaid on the MNI152 brain (middle and bottom).
Voon et al. Translational Psychiatry           (2020) 10:84 Page 3 of 9
explanatory examples of changes in transition and prob-
ability, and a short block of 50 trials in the same format as
the experimental task but with different stimuli. The task
was run with Cogent 2000 (http://www.vislab.ucl.ac.uk/
cogent.php) on Matlab R2011a (Mathworks, Natick,
USA). See Supplemental Materials for an analysis on
existing datasets comparing this shortened (two-block)
version of the task with the typical three-block version: we
showed that the average main outcome measure was
highly correlated between the two versions.
PET imaging
All subjects underwent PET scanning three times: first
using the MOR-ligand [11C]carfentanil, then with the
SERT-ligand [11C]MADAM, and finally with the dopa-
mine precursor ligand [18F]FDOPA. The syntheses of
these tracers have been described in detail previously22,24.
The PET imaging was performed with an high resolution
research tomograph (Siemens Medical Solutions, Knox-
ville, TN, USA) PET scanner used in 3D list mode with
scatter correction. A transmission scan was performed
before each PET scan with a [137Cs] rotating point source.
The dynamic scanning times were 51, 90, and 90min for
[11C]carfentanil, [11C]MADAM, and [18F]FDOPA,
respectively. All three PET scans were conducted in the
same day at fixed intervals: [11C]carfentanil scan at
0900–1000 h, regular hospital lunch at 1100–1200 h, [11C]
MADAM scan at 1200–1300 h and [18F]FDOPA scan at
1430–1530 h. One [11C]carfentanil scan and three [18F]
FDOPA scans were performed on a separate day due to
tracer production failure or scanner malfunction. Head
movements were minimized using a personalized ther-
moplastic mask or a Velcro strap, and recorded with a
stereotaxic infrared camera (Polaris Vicra, Northern
Digital, Waterloo, Canada). One [11C]carfentanil scan,
three [18F]FDOPA scans and three [11C]MADAM scans
were excluded due to scanner malfunction or subject
withdrawal. Thus, the final sample sizes were 7 BED, 15
PG, and 16 controls with [11C]carfentanil, 7 BED, 13 PG,
and 16 controls with [11C]MADAM and [18F]FDOPA.
The preprocessing and analysis has been described in
detail previously22. Briefly, PET images were corrected for
between-frame motion and coregistered with individual
anatomical T1-weighted magnetic resonance imaging
(MRI) using Statistical Parametric Mapping software
(SPM8, http://www.fil.ion.ucl.ac.uk/spm/software/spm8/).
Time-activity data were extracted using regions of interest
(ROI) for the mean NAcc area, caudate, putamen and
mOFC, which were determined from the individual T1-
weighted MR images using FreeSurfer automatic parcel-
lation (Fig. 1b, top) (version 5.3.0, http://surfer.nmr.mgh.
Harvard.edu/) as described earlier25–27. Note that the
automated mOFC ROI includes both vmPFC and mOFC
regions and is referred to in this study as vmPFC/mOFC
(Fig. 1b). The simplified reference tissue model was applied
to calculate [11C]carfentanil and [11C]MADAM estimates of
specific binding relative to non-displaceable BPs (BPND)
28.
[18F]FDOPA influx rate constant (Ki) was determined using
the Patlak plot using the reference region as the input
function29. The occipital cortex was designated as the
reference region for [11C]carfentanil and [18F]FDOPA, and
the cerebellar cortex was the reference region for [11C]
MADAM. Different reference regions ensure there is no
specific tracer binding in the reference region (in the case of
[11C]MADAM, there is specific binding in the occipital
cortex but no specific binding in the cerebellar cortex30; for
[11C]carfentanil and [18F]FDOPA, there is no specific
binding in the occipital cortex31,32).
Analysis
All PET data were tested for outliers (>3 standard
deviation (SD) from group mean) and normality of dis-
tribution (Shapiro Wilkes test p > 0.05). The computa-
tional analysis for the two-step task has been extensively
described previously4,33. In brief, we fit choice data of each
participant to a hybrid algorithm that combined model-
free (i.e., reinforcement learning) and model-based
learning algorithms. This model estimates five para-
meters based on the behavioural data for each participant:
a choice reliability parameter (β) a learning rate (α), a
reinforcement eligibility parameter (λ), a perseveration
rate, and a weighting parameter (w, which extends from 1
(purely model-based) to 0 (purely model-free). We analyse
only this final parameter, described as wr=w for the
reward condition, and wl=w for the loss condition.
Two healthy controls did not complete the two-step
task for loss outcomes. We tested wr and wl for outliers
(>3 SD from group mean) and normality of distribution
(Shapiro Wilkes test p > 0.05). As the scores were nor-
mally distributed we used parametric analyses. We com-
pared wr between groups in the behavioural analysis using
a one-way ANOVA (but did not conduct any group
comparisons for wl as only healthy volunteers were tested
in the loss condition). For the relationship with neural
regions associated with the PET ligands, we conducted six
stepwise multiple linear regressions with backwards
elimination, with either wr or wl as the dependent variable
and the mean bilateral NAcc, caudate, putamen and
vmPFC/mOFC of each PET ligand data as the indepen-
dent variables (no multicollinearity was detected with VIF <
10; homoscedascity of residuals and normality of residuals
were confirmed). The wr analysis included healthy con-
trols, PG, and BED; since only healthy controls were
tested in the loss condition, the wl model included only
healthy controls. For these models, p < 0.0083 was con-
sidered significant (after Bonferroni correction for six
regression analyses: one model for each ligand, for both
reward and loss).
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Results
We assessed 17 healthy controls, 15 patients with PG,
and 7 patients with BED (see Table 1 for demographic
details, and see previous publications for additional clin-
ical details22,34). Age did not differ between groups (p=
0.35), though there was a group effect of body mass index
(BMI) (p= 0.003, driven by an increased BMI in the BED
population) and on the Beck Depression Inventory (BDI)
(p < 0.0005, driven by higher BDI scores in both patient
populations). There were also group differences across all
gambling measures (driven by higher scores in the PG
group) and binge eating measures (driven by higher scores
in the BED group); all p < 0.01 (see Table 1).
We first analysed the behavioural results alone to test if
the groups differed on measures of model-based and
model-free control on wr (extracted from the computa-
tional model that putatively describes the degree of
model-based or model-freeness of a subject). There were
no significant group differences in wr between groups
(healthy volunteers: 0.289 (0.254); PG: 0.139 (0.126); BED:
0.247 (0.232); F(2,34)= 1.70, p= 0.12) (wl was not
compared between groups as only healthy volunteers were
tested).
We have also tested whether other computational
parameters differed between groups. There were no sig-
nificant differences with other parameters including
learning rates, temperature or reinforcement eligibility
parameter. There was a significant group difference in
perseveration, or the tendency to select the same choice in
the first stage irrespective of outcome (PG: 0.06 (0.14),
Healthy volunteers 0.16 (0.10), BED: 0.3 (0.26) (p= 0.009)
with posthoc analysis showing differences between PG
and BED (p= 0.007). These findings are consistent with
high perseveration scores in BED previously reported4.
We compared the model fits and did not show a differ-
ence between groups (negative log likelihoods (−LL): w_r:
control: 142.08 (27.60); PG 154.06 (29.57); BED 137.74
(43.11); p= 0.46; w_l: 138.65 (37.17)). We note that the
model fit for this analysis was largely similar to our existing
healthy control data set (see Supplemental Materials). We
also ran a supplementary analysis with [11C]MADAM and
w_r and [11C]carfentanil and w_l with −LL for reward and
loss included as a variable respectively with both models
remaining significant (reward: p= ; loss: p= 0.007).
PET imaging data
Reward
The linear regression for wr (collapsed across all three
groups) showed a significant relationship with [11C]
MADAM BP (R2= 0.330, F= 4.791, p= 0.008) (which was
significant after Bonferroni correction). The NAcc was not
associated with wr and was subsequently removed from the
model. The final model showed that wr was significantly
negatively correlated with vmPFC/mOFC (Beta=−0.653,
t=−3.406, p= 0.002), positively correlated with putamen
(Beta= 0.421, t= 2.352, p= 0.040), and marginally asso-
ciated with caudate (Beta= 0.332, t= 1.876, p= 0.071)
[11C]MADAM BP. In sum, greater goal-directed control
(and weaker habitual control) was associated with putamen
[11C]MADAM BP, while greater habitual control (and
weaker goal-directed control) was associated with vmPFC/
mOFC [11C]MADAM BP. There were no significant rela-
tionships between wr and [
18F]FDOPA (R2= 0.081, F=
2.554, p= 0.121) or [11C]carfentanil BP (R2= 0.008, F=
0.259, p= 0.614). See Fig. 2a, b.
Loss
The linear regression for wl and [
11C]carfentanil BP was
significant with all regions included in the model (R2=
0.472, F= 10.728, p= 0.007) (note wl includes only healthy
participants, as this version of the task was only run in
healthy participants) (which remained significant after
Bonferroni correction). However, the vmPFC/mOFC, cau-
date, and putamen were not significantly associated with wl,
and were therefore removed from the model. In the final




BED (N= 7) PG (N= 15)
Mean age (SD) 43.29 (11.10) 49.43 (5.09) 42.60 (11.81)
Males 8 0 8
Mean BMI (SD) 24.82 (2.10) 30.87 (6.58) 25.41 (3.64)
Mean BDI (SD) 2.82 (3.09) 15.43 (9.62) 14.36 (7.76)
SOGS 0.1 (0.3) 0.4 (0.5) 13.3 (2.3)
Duration of problem
gambling (y)
n.a. n.a. 11.6 (7.3)
Gambling per week (€) 3.9 (7.4) 2.9 (4.6) 152 (149)
Gambling per
week (h)
0.5 (1.2) 0.5 (1.2) 8.7 (7.2)
Gambling debt (€) 0 (0) 0 (0) 18,000 (15,600)
Binge eating scale 2.1 (2.1) 30.9 (4.6) 4.4 (4.4)
Yale food
addiction scale
5.4 (3.4) 42.3 (6.5) 9.1 (9.5)
DEBQ emotional 20.5 (5.0) 50.0 (8.3) 21.2 (8.7)
DEBQ external 23.7 (5.3) 37.5 (6.3) 26.1 (7.3)
DEBQ restrained 24.8 (6.8) 35.3 (3.4) 20.9 (10.6)
Duration of problem
eating (y)
n.a. 18.1 (14.9) n.a.
SD standard deviation, BED Binge eating disorder, PG pathological gambling, BMI
body mass index, BDI Beck depression inventory, DEBQ the Dutch eating
behavior questionnaire, SOGS south oaks gambling screen, n.a. not applicable.
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model, wl, or greater goal-directed control (or impaired
habitual control) toward losses, was significantly positively
correlated with bilateral NAcc [11C]carfentanil BP (Beta=
0.687, t= 2.275, p= 0.007). See Fig. 2c.
The linear regression for wl and [
18F]FDOPA showed
only a trend (after Bonferroni correction) in the rela-
tionship between wl (R
2= 0.337, F= 5.598, p= 0.037);
this was no longer significant after Bonferroni correction.
The vmPFC/mOFC, caudate and NAcc were not sig-
nificantly associated and were removed from the model.
The final model of wl and bilateral putamen [
18F]FDOPA
(Beta=−0.581, t=−2.366, p= 0.037), such that higher
putaminal [18F]FDOPA was associated with impaired
goal-directed control (or greater habitual control) toward
losses but critically was not significant after correction
(see Fig. 2d). Given previous positive findings13, we also
specifically tested a regression analysis with NAcc [18F]
FDOPA for w_r and w_l, and show no significant findings
(p= 0.98 and p= 0.32, respectively).
There were no significant relationships between wl and
[11C]MADAM BP (R2= 0.038, F= 0.475, p= 0.504).
Valence specificity and behavioural measures of model-
based and model-free control
To assess specificity of the effect of the tracer on valence
we reran the multiple regression analysis controlling for
the opposing valence. As there was no evidence of mul-
ticollinearity between w for gain and loss (Tolerance=
0.74, VIF= 1.34), we conducted a secondary analysis of
the regression analysis for [11C]MADAM and w_r
including w_l into the model. The overall model including
caudate and vmPFC/mOFC (but not putamen) remained
significant at p= 0.014 (caudate p= 0.018; vmPFC/
mOFC p= 0.006). Similarly, the regression analysis for
[11C]carfentanil and w_l including w_r into the model also
remained significant at p= 0.007 with only NAcc in the
model (NAcc p= 0.007). The regression analysis for [18F]
FDOPA and w_l including w_r into the model also
showed an overall model p value of 0.04 with only puta-
men in the model (putamen p= 0.04). Put together, these
secondary findings highlight the specificity of [11C]
MADAM and vmPFC/mOFC for w_r and [11C]carfentanil
and NAcc for w_l.
For the purposes of exploring the trade-off between
goal-directed and habitual effects and the relationship
with neurotransmitter levels, we conducted supplemen-
tary analyses with the behavioural based model-based and
model-free control as the independent variables rather
than w. For [11C]MADAM and reward, there was no
significant relationship with either model-based on
model-free control. For [11C]carfentanil and loss, greater
model-based control was significantly associated with a
Fig. 2 The neurochemical substrates of goal-directed control for rewards and losses. a Significant relationship between the relative balance of
model-based and model-free control for rewards and medial orbitofrontal cortex (mOFC)/ventromedial prefrontal cortex (vmPFC) [11C]MADAM BP
(across all participants). b Nonsignificant relationship between the relative balance of model-based and model-free control for rewards and putamen
[11C]MADAM BP (across all participants). c Significant relationship between the relative balance of model-based and model-free control for losses and
nucleus accumbens (NAcc) [11C]carfentanil BP (healthy controls only). d Nonsignificant relationship between the relative balance of model-based and
model-free control for losses and putamen [18F]FDOPA. **p < 0.0083 (alpha Bonferroni-corrected for six multiple comparisons).
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model (p= 0.019) with a positive correlation with NAcc
[11C]carfentanil BP (t= 3.24, p= 0.008); and greater
model-free control was significantly associated with a
model (p= 0.01) with a negative correlation with NAcc
[11C]carfentanil BP (t=−3.04, p= 0.01).
Discussion
We reveal a differential role for prefrontal and striatal
serotoninergic systems in mediating the balance of goal-
directed and habitual control in the reward domain: lower
mOFC/vmPFC, but higher putamen [11C]MADAM BP
correlated with a shift toward goal-directed control;
however, the latter relationship was not specific when
controlled for the opposing valence (loss). In the loss
domain, we also find a differential relationship between
opioidergic systems and both a positive correlation with
goal-directed control and a negative correlation with
NAcc [11C]carfentanil BP.
Opioid peptides in goal-directed control
In the loss domain, we also found a positive relationship
between the opioidergic system and goal-directed control
and a negative relationship with habit-directed control.
Here, greater NAcc [11C]carfentanil BP may reflect either
greater MOR density or lower endogenous synaptic pep-
tide opioid levels, which compete for binding with [11C]
carfentanil. These findings are consistent with preclinical
evidence suggesting blockade of endogenous opioid
activity in rodents by the competitive opioid receptor
antagonist naloxone during acquisition learning of food
rewards shifts behavior toward habitual control, and
decreases sensitivity to changes in the value of reward14.
This effect was restricted to the acquisition of goal-
directed actions, and not during performance in the test
phase, suggesting a specific effect of MOR antagonism
during goal-directed learning. An alternate explanation
lies in the effect of opioids on aversive processing: opioids
decrease pain ratings particularly in the expectation of
pain relief35, and decrease non-painful aversive responses
such as conditioned aversion in rodents36. In healthy
humans, blocking MOR with naloxone during a gamble
task increased the subjective aversive ratings to monetary
loss outcomes36. Furthermore, naloxone increases blood
oxygen level-dependent activity during loss outcomes in
caudal and subgenual cingulate, bilateral insula, thalamus,
and visual cortex; caudal cingulate activity correlates with
aversive ratings36. Thus, in our data, an alternate plausible
explanation may be that endogenously lower opioid
peptides enhances the aversiveness of monetary loss, thus
improving goal-directed control to losses. Note that
although MOR stimulation is associated with striatal
dopamine release via GABAergic mechanisms in the
ventral tegmental area37, we did not observe any rela-
tionship between [18F]FDOPA and goal-directed control
in our study, nor any relationship between [18F]FDOPA
and [11C]MADAM or [11C]carfentanil BP.
A differential role for prefrontal and striatal serotonergic
systems
Perhaps the most interesting finding emerging from our
study is a potential differential relationship between pre-
frontal and striatal serotonergic systems in mediating the
balance between goal-directed and habitual control. In
rodents, decreasing forebrain 5-HT and systemic 5HT2C
antagonism enhances compulsive cocaine seeking, an
effect which was reversed by both a 5HT2C agonist and a
selective serotonin reuptake inhibitor14. Furthermore,
overexpression of dorsolateral striatal 5-HT6 receptors
decreases habitual control in rodents15. In healthy
humans, central serotonin depletion enhances habitual
responding17 and impairs goal-directed control to
rewards, while enhancing goal-directed control to losses6.
Patients with obsessive–compulsive disorder (with puta-
tive impairments in serotonergic function) show impaired
goal-directed control for rewards and enhanced goal-
directed control for losses33.
It is worth noting that SERT BP is interpreted in terms
of serotonin terminal density (SERT density), which can
be either primary or adaptive in response to endogenous
serotonin level changes; these have opposing implications
for serotonin levels. If we presume that low SERT BP
reflects fewer serotonergic terminals, and hence lower
serotonergic activity, our prefrontal results support pre-
vious findings that low forebrain serotonin in rodents
enhances compulsive cocaine seeking14 and central ser-
otonin depletion in healthy humans impairs goal-directed
control and shifts behavior toward habitual responding
for rewards17. However, we fail to confirm previous stu-
dies showing valence-dependent effects on serotonin on
goal-directed processing6 (we show no effect in the loss
domain), which is inconsistent with previous work
showing a key role of serotonin in loss or punishment
processes6,38.
Presynaptic dopamine synthesis and habitual control
There are conflicting preclinical and human reports
regarding dopaminergic function in goal-directed and
habitual control. In rodents, pharmacologically enhancing
dopamine (with amphetamine) accelerates habit forma-
tion7, a process reversed by D1 antagonism (but enhanced
by D2 antagonism)39; selective nigrostriatal dopaminergic
lesions impair habit formation8. In contrast, in healthy
humans, depletion of the dopamine precursor increases
habitual control9. The severity of Parkinson’s disease,
characterized by dopaminergic deficits, is associated with
impairments in goal-directed control9; patients tested off-
medication show impaired goal-directed control. Phar-
macological enhancement of dopamine with levodopa
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increases goal-directed control in both Parkinson’s disease
patients11 and healthy controls10; although note this may
not generalize to all individuals, as a more recent study
found that levodopa decreased habitual control, with
increases in goal-directed control only seen in individuals
with a high working memory capacity12. Nevertheless,
greater ventral striatal presynaptic dopamine synthesis,
measured using F-DOPA PET, correlates with greater
goal-directed control13. These human studies contrast
with the preclinical literature9,11 and may be related to
task differences such as overtraining in rodent relative to
human studies, lack of anatomical specificity of dopami-
nergic medication challenges in humans, or overlap of
neural substrates underlying goal-directed and habitual
control3.
Our observations in healthy controls are more con-
sistent with the preclinical literature: we show a marginal
relationship between greater presynaptic dopamine
synthesis in putaminal regions and habitual control in the
loss domain which was no longer significant after multiple
correction. A previous study showed a weak positive
relationship between [18F]FDOPA and goal-directed
control to rewards in 29 healthy controls13. However,
we were unable to replicate these findings. Our lack of
positive findings in the reward domain should be inter-
preted with caution, as we may not have had adequate
power to replicate this effect. However, the negative
relationship we observed with in the loss domain could
imply a differential relationship between the role of
dopamine in goal-directed and habit control for rewards
versus losses.
Limitations
Our study is the first to investigate the role of three
neurochemical systems—serotonergic, dopaminergic, and
opioidergic—in goal-directed and habitual control. As
such, while we reveal a number of interesting potential
relationships, we are limited by both inherent ambiguities
in the interpretation of BP effects, and a relative dearth of
similar investigations in humans. Furthermore, while our
study was adequately powered for within-group compar-
isons, our lack of a group effect may simply reflect
inadequate power to detect between-group differences.
This lack of power could also account for our lack of
group differences on our behavioural measure (wr); pre-
vious studies have shown this measure to be generally
compromised across disorders of compulsitivity3–5.
We also tested whether other computational parameters
differed between groups. There were no significant dif-
ferences with other parameters including learning rates,
temperature or reinforcement eligibility parameter. There
was a significant group difference in perseveration, the
tendency to select the same choice in the first stage
irrespective of outcome (PG: 0.06 (0.14), healthy
volunteers: 0.16 (0.10), BED: 0.3 (0.26); p= 0.009) with a
posthoc analysis showing differences between PG and
BED (p= 0.007). Despite our small sample size of patients
with BED, we replicate the finding of increased perse-
veration irrespective of outcome, which we previously
reported in a much larger sample: patients with BED
showed increased perseveration on this task compared to
obese participants without BED4. This fits in with a larger
experimental and clinical literature reporting cognitive
inflexibility in BED: patients with BED show decreased
cognitive flexibility on a neuropsychological battery
compared to either healthy controls or patients with
anorexia40 (for a review of the literature, see ref. 41). This
impairment in cognitive flexibility could contribute to the
symptoms of BED by making patients less able to change
their decisions about food consumption after changing
environmental outcomes (e.g., the food losing value after
satiety, or nausea or discomfort as a result of overeating).
In addition, our findings in the reward domain were
strengthened by the inclusion of both healthy controls
and a transdiagnostic psychiatric population; in contrast,
our findings in the loss domain were limited to the healthy
population. In future, it would be essential to extend our
transdiagnostic results to the loss domain, but also
investigate samples large enough to characterize any
between-group relationships in each neurochemical sys-
tem and its role in goal-directed and habitual control.
Conclusions
We highlight a potential role for dopaminergic, opioi-
dergic and serotonergic mechanisms in arbitrating
between behavioral controllers. In the reward domain, we
showed a differential role for prefrontal and striatal ser-
otonergic mechanisms, which were associated with habi-
tual and goal-directed control, respectively. In the loss
domain, we found the NAcc opioidergic system was
positively associated with goal-directed control, and more
tentatively, that the putaminergic dopaminergic system
was associated with habitual control. These findings begin
to reveal the complex neurochemical substrates of a key
aspect of decision-making. Uncovering these mechanisms
could be crucial to developing interventions that target
these behavioural strategies in the context of psychiatric
disorders.
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